Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...

Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...

Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring ...

Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

Orbis Medicines raises €90M Series A led by NEA for macrocycle drug development, with backing from Eli Lilly, Cormorant Asset ...

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown ...

San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million ...